- •
Pleural malignancies are ideal for novel therapeutic approaches, because they are invariable fatal with few treatment options.
- •
Intrapleural chemotherapy has only marginal benefit in pleural malignancies, but may prove efficacious with hyperthermic chemotherapy administered in combination with maximal tumor debulking.
- •
Intrapleural immunotherapies may be most effective in those patients with early-stage pleural malignancy, such as mesotheliomas limited to the parietal pleura, and may prove superior
Intracavitary Therapeutics for Pleural Malignancies
Section snippets
Key points
IP chemotherapy
Pleural malignancies such as mesothelioma are characterized by predominantly locoregional spread of disease for which surgical resection can be attempted, but with the certainty of residual microscopic disease. Therefore, there is a rationale for attempted local control of pleural malignancies by IP instillation of cytotoxic chemotherapeutic agents. For example, Refaely and colleagues11 in 2002 reported their experience with intraoperative IP hyperthermic cisplatin chemotherapy in 15 patients
IP immunotherapy
Among the malignancies of the pleural space, MM has been thought to be resistant to immunotherapy compared with more classically immunogenic tumors such as melanoma or renal cell carcinoma. In these diseases, exogenous cytokines, monoclonal antibodies, and tumor vaccines have contributed to antitumor responses. Immunotherapy has been attempted in MM, despite observations of a significant immunosuppressive tumor microenvironment.20, 21, 22 In addition to the tumor’s innate mechanisms of immune
IP gene therapy
Advances in molecular genetics and gene transfer technology facilitated the development of gene therapy: the modification of the genetic makeup of cells for therapeutic purposes. The concept of gene therapy now encompasses the treatment of any pathophysiologic state based on the transfer of genetic material, including complementary DNA (cDNA), full-length genes, small-interfering RNA (si-RNA), or oligonucleotides. This definition also includes approaches involving delivery of genetically
Vectors used in pleural gene therapy
The first requirement for successful gene therapy is efficient gene delivery and a variety of viral and nonviral gene transfer vectors have been developed.36, 37 As summarized in Table 1, each of these vectors has certain advantages with regard to DNA carrying capacity, types of cells targeted, in vivo gene transfer efficiency, duration of expression, and induction of inflammation.
IP delivery of tumor suppressor genes
One of the primary approaches to cancer gene therapy has been mutation compensation: the replacement of absent or mutated tumor suppressor genes responsible, in part, for the malignant phenotype of the cancer cell. Intratumoral delivery of the wild-type p53 (wt-p53) gene, for example, has been used in human gene therapy trials for lung cancer and other solid tumors. Despite most mesotheliomas having wt-p53, p53 function may be abnormal in mesothelioma cells secondary to p53 binding by inhibitor
Summary
Pleural malignancies are ideal for novel therapeutic approaches, because they are invariably fatal, with few treatment options. In addition, research efforts into the efficacy of novel therapies are aided by the ease of access of the pleural space for thoracoscopic examination and/or pleural fluid sampling. IP chemotherapy has only marginal benefit in pleural malignancies, but may prove efficacious with hyperthermic chemotherapy administered in combination with maximal tumor debulking. IP
References (81)
- et al.
Empyema following lung cancer resection: risk factors and prognostic value on survival
Ann Thorac Surg
(1982) - et al.
Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer
J Thorac Cardiovasc Surg
(1981) - et al.
Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread
Ann Thorac Surg
(2001) - et al.
Innovative therapies: intraoperative intracavitary chemotherapy
Thorac Surg Clin
(2004) - et al.
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study
J Thorac Cardiovasc Surg
(2009) - et al.
Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion
Chest
(2002) - et al.
Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis
Ann Thorac Surg
(2004) - et al.
Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion
J Thorac Oncol
(2010) - et al.
Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma
Cancer Lett
(1996) - et al.
Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion
Chest
(1993)
Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer
Chest
Methods of gene delivery
Hematol Oncol Clin North Am
Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions
J Biol Chem
Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic
Curr Opin Immunol
The role of the bystander effect in suicide gene therapy
Eur J Cancer
Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma
Ann Thorac Surg
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma
Ann Thorac Surg
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions
Mol Ther
Malignant pleural mesothelioma: Update on treatment options with a focus on novel therapies
Clin Chest Med
Advances in the diagnosis, evaluation and management of malignant pleural mesothelioma
Respirology
Postoperative empyema and survival in lung cancer
Br Med J
Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment
N Engl J Med
Empyema in lung cancer–the cloud with a silver lining
JAMA
Influence of postoperative empyema on survival after pulmonary resection for bronchogenic carcinoma
Br Med J
The relationship between postoperative empyema and long-term survival after pneumonectomy. Results of surgical treatment of bronchogenic carcinoma
Scand J Thorac Cardiovasc Surg
Postoperative intrapleural BCG in lung cancer: lack of efficacy and possible enhancement of tumour growth
Thorax
Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report
Cancer Immunol Immunother
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study
Am J Clin Oncol
Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer
Chemotherapy
Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study
Oncology
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma
Am J Respir Cell Mol Biol
Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma
Growth Factors
High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma
J Clin Immunol
The alveolar macrophage: immune derangement and asbestos-related malignancy
Semin Oncol
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma
Ultrastruct Pathol
Effect of interferon-alpha 2a on malignant mesothelioma
J Interferon Res
Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
Cancer
Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma
Cancer
Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer
Cancer Immunol Immunother
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study
Br J Cancer
Cited by (5)
Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T Cell suppression
2016, Journal of Thoracic OncologyCitation Excerpt :The pleural cavity is a convenient compartment to administer different treatment modalities in close approximation to the tumor and potentially minimize systemic toxicities. Different intrapleural treatment options are now under investigation.9 Pleural effusion (PE) accompanies mesothelioma in approximately 70% of the cases, predominantly in the epithelioid subtype.10
Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion
2015, Journal of Cardiothoracic SurgeryMultimodal management of malignant pleural mesothelioma: Where are we today?
2014, European Respiratory JournalPressurized intraThoracic aerosol chemotherapy (PITAC)
2014, PIPAC: Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer Under Pressure